Alogliptin

• Type 2 Diabetes Mellitus
• Blood Sugar Control
• Glycemic Management

Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus. This oral medication helps control blood sugar levels by enhancing the body's natural ability to regulate glucose through the incretin hormone system.

Mechanism of Action

Alogliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the rapid degradation of incretin hormones, particularly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By blocking DPP-4, alogliptin increases and prolongs the activity of these incretins. GLP-1 and GIP stimulate glucose-dependent insulin secretion from pancreatic beta cells, suppress glucagon release from alpha cells, slow gastric emptying, and promote satiety. The glucose-dependent nature of this mechanism means that alogliptin has a low risk of causing hypoglycemia when used alone.

Available Formulations

Alogliptin is available as oral tablets in 6.25 mg, 12.5 mg, and 25 mg strengths. It is also available in fixed-dose combinations with metformin (alogliptin/metformin) and with pioglitazone (alogliptin/pioglitazone). The tablets can be taken with or without food.

Medical Uses

Alogliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It can be used as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, pioglitazone, and insulin. Clinical trials demonstrated significant reductions in HbA1c when alogliptin was used alone or in combination therapy. The EXAMINE trial showed cardiovascular safety in patients with recent acute coronary syndrome.

Dosing Guidelines

The recommended dose is 25 mg once daily. Alogliptin can be taken at any time of day, with or without food. Dose adjustment is required for patients with renal impairment: 12.5 mg daily for moderate impairment (CrCl 30-59 mL/min) and 6.25 mg daily for severe impairment (CrCl 15-29 mL/min) or end-stage renal disease requiring dialysis. No dose adjustment is needed for mild renal impairment or hepatic impairment. When combined with insulin or insulin secretagogues, the dose of those medications may need to be reduced to minimize hypoglycemia risk.

Important Safety Information

Alogliptin has been associated with reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Patients should be informed of the characteristic symptoms of acute pancreatitis and instructed to discontinue alogliptin promptly if such symptoms occur. Post-marketing reports have described serious hypersensitivity reactions, including anaphylaxis, angioedema, and severe cutaneous adverse reactions (Stevens-Johnson syndrome). Heart failure has been reported with DPP-4 inhibitors; patients should be monitored for signs and symptoms.

Drug Interactions

Alogliptin has minimal drug interactions due to its primarily renal elimination without significant cytochrome P450 metabolism. When combined with insulin or insulin secretagogues (sulfonylureas, meglitinides), the dose of these medications may need to be reduced due to increased hypoglycemia risk. No clinically significant interactions have been observed with metformin, pioglitazone, atorvastatin, glyburide, fluconazole, ketoconazole, cimetidine, cyclosporine, digoxin, or warfarin.

Special Populations

There are no adequate studies of alogliptin in pregnant women; use during pregnancy only if clearly needed. It is unknown whether alogliptin is excreted in human breast milk; caution should be exercised when administering to nursing mothers. Safety and efficacy have not been established in pediatric patients. No dose adjustment is needed for elderly patients based on age alone, though renal function should be assessed. Patients with moderate to severe renal impairment require dose reduction. No dose adjustment is needed for hepatic impairment, though use with caution in patients with liver disease due to post-marketing reports of hepatic failure.